About: Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 07 December 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2018 (uk) article scientifique publié en 2018 (fr) im Dezember 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 2018 (ast) scientific article published on 07 December 2018 (en)
publication date	wds:Q60045997-DD18702F-FDF3-457C-8131-EAD557C78306
publication date	2018-12-07 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q60045997-263794E1-C9E6-4C5F-AB83-C0A59C093C70
language of work or name	English
cites work	wds:Q60045997-00072919-CB32-4979-A689-743C66CB26A7 wds:Q60045997-0250A15F-939F-4E9D-996E-5195013A7FA2 wds:Q60045997-037D1E01-1C9A-49BB-9CA7-05238F626958 wds:Q60045997-12F397C7-3320-400E-855C-F33E48535088 wds:Q60045997-15190F74-A85B-4AF0-8E52-6680D591A04A wds:Q60045997-164250FA-1338-4710-A949-8DD5464265F0 wds:Q60045997-1862BF9B-613E-44AB-8490-80AE7D36682B wds:Q60045997-1BD4FF61-2CD7-4E18-A306-F9075E77ED4C wds:Q60045997-20114DF0-0876-46E0-91AC-02925778D8E5 wds:Q60045997-269F655D-379D-4ED4-8CB4-D935E8871E42 wds:Q60045997-2A7B55C8-38AA-4F57-B1A8-E4E0B7B5ECE1 wds:Q60045997-2D239F5E-02DD-43BE-8990-A4D29F742CBD wds:Q60045997-2FC5B3E1-E419-4328-B088-2C2D52B37E15 wds:Q60045997-327829B4-B41D-4EEE-B1F3-322C3E474F2A wds:Q60045997-44FBED62-707E-421B-888F-445E5458D962 wds:Q60045997-47FE2B28-0B63-406E-93EC-9D9070459496 wds:Q60045997-4F26B6CE-087D-4D79-AC57-4F72938DAD1D wds:Q60045997-5DC1C080-DA0F-463E-8B4A-752F31E5103D wds:Q60045997-5E83FEB1-EF5E-4936-8581-51A19719896D wds:Q60045997-5EEEA13F-9755-4347-867A-F63F5C88F5A0 wds:Q60045997-639596D1-6265-484B-A9F3-9819ACE8CB2C wds:Q60045997-675A4B44-5098-4EAB-9077-D4BA49ED1458 wds:Q60045997-7068E58B-5A04-4D14-91D1-4F7A7078ADBB wds:Q60045997-7251D500-0048-4C84-9EEF-297328CE65C0 wds:Q60045997-79AA1A55-0857-44CC-BD8F-90F7A1E5B35F wds:Q60045997-83F1F7AE-851B-4681-85BD-A45E26884CBC wds:Q60045997-867B4B3E-8737-4610-8E6B-0897CF759D86 wds:Q60045997-921BE85E-F4D9-4CBA-BA1C-2D1798645154 wds:Q60045997-A21F9251-AC22-4D37-90B4-BD2040BD6453 wds:Q60045997-AE12FCF4-3FF1-4829-8E4A-DA0C6D38E8B2 wds:Q60045997-B3D4E592-4EE6-41E1-AAE7-B346C1EF3B7F wds:Q60045997-BACE8142-BA1E-4DCB-9E44-0F15E6D51152 wds:Q60045997-BFA7BBCB-8E4C-4BEB-BA73-D221F6A29136 wds:Q60045997-C1D34218-6460-4339-B439-58D04DA63D7C wds:Q60045997-C33FDF96-8D63-473B-AA8E-2B60DAF1DD5F wds:Q60045997-CDE66E69-A32D-4ACB-A6CE-9E83B3340D5D wds:Q60045997-D0A767D1-49E4-4927-8638-A3312160432A wds:Q60045997-D2C66669-E17E-4554-AB76-366439EA6704 wds:Q60045997-D5942CE3-13D4-4BFE-8F5C-4739FB7FD4B0 wds:Q60045997-D98B0D9B-1A75-43DF-919A-E61AEAFC3B11 wds:Q60045997-E474B56C-8385-4296-9F0B-684E71699C46 wds:Q60045997-EEE7A839-5323-4C3C-97FB-1A454C46672C wds:Q60045997-F5B8B540-593C-42CA-B2E8-07C9F76CFCF6
cites work	Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Sodium-glucose cotransport Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension In-hospital costs of diabetic foot disease treated by a multidisciplinary foot team Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes 14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys Assessment of cardiovascular risk in hypertensive patients: a comparison of commonly used risk scoring programs Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
author name string	wds:Q60045997-6B0EC09F-78F6-4029-8729-539A9847ABE7 wds:Q60045997-6BC068B8-CDDB-4C00-9D17-72D2AC0417D2
author name string	Jessica W Skelley

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software